Combining PRIMA‐1met and Oxaliplatin for Colorectal Cancer Treatment
Author Information
Author(s): Li Xiao‐lan, Zhou Jianbiao, Tang Nicole Xin‐Ning, Chai Yi, Zhou Meng, Gao Ai‐di, Lu Zhong‐kai, Min Han
Primary Institution: The Affiliated Suzhou Hospital of Nanjing Medical University
Hypothesis
The study explores the combination therapy of PRIMA‐1met and L‐OHP for colorectal cancer with different p53 status.
Conclusion
The combination of PRIMA‐1met and L‐OHP shows enhanced efficacy and reduced toxicity in colorectal cancer treatment.
Supporting Evidence
- The combination therapy showed heightened cytotoxicity in CRC cells.
- RNA-seq analysis revealed differential responses between p53-wild type and p53-mutant cells.
- In vivo studies demonstrated enhanced efficacy of combined therapy over PRIMA‐1met alone.
- The combination mitigated L‐OHP‐induced toxicity.
Takeaway
This study found that using two drugs together can help fight colon cancer better and with fewer side effects than using just one.
Methodology
The study used cell viability assays, wound healing assays, colony formation assays, RNA sequencing, and in vivo xenograft models to assess the effects of the drug combination.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website